The Readout Loud

350 Folgen

1. 248: The next CRISPR fight, cheaper insulin, & an FDA shuffle

   Vom: 2.3.2023
2. 247: Vertex vs. insurers, Moderna's future, & biotech's long winter

   Vom: 23.2.2023
3. 246: Vas Narasimhan on the future of pharma, plus Moderna’s promise & a biotech presidential bid

   Vom: 16.2.2023
4. 245: The return of bird flu and the effects of pandemic fatigue

   Vom: 9.2.2023
5. 244: Pharma blockbusters, pandemic policy, & legal chicanery

   Vom: 2.2.2023
6. 243: George Scangos' retirement, annual Covid vaccines, an Alzheimer's drug rejection

   Vom: 26.1.2023
7. 242: How blockbusters get made, new vaccines for RSV, and mRNA's Q score

   Vom: 19.1.2023
8. 241: #JPM23 in review, the year ahead, & the merits of Miami

   Vom: 12.1.2023
9. 240: #JPM23, the future of Alzheimer's, & rising Covid variants

   Vom: 5.1.2023
10. 239: 2022 in review, CEO indictments, & the year ahead

    Vom: 22.12.2022
11. 238: Leaky health data, ASH22, & what it takes to get booed by your peers

    Vom: 15.12.2022
12. 237: The 'electric vehicles' of pharma, Illumina's boondoggle, & a Theranos sentencing

    Vom: 8.12.2022
13. 236: Wither PhRMA, Alzheimer's treatment data revealed, and the first fecal microbiome drug approval

    Vom: 1.12.2022
14. 235: LIVE from the STAT Summit

    Vom: 17.11.2022
15. 234: Biogen's new CEO, how the midterms affect science, & a biotech bankruptcy

    Vom: 10.11.2022
16. 233: How the biotech revolution could come apart at the seams

    Vom: 3.11.2022
17. 232: Anti-science at the polls, a biotech odd couple, & the stakes of the midterms

    Vom: 27.10.2022
18. 231: BU's Covid tinkering, FDA on trial, & why it's hard to take drugs off the market

    Vom: 20.10.2022
19. 230: BIO's messy transition, mRNA's future, & Biogen's next CEO

    Vom: 13.10.2022
20. 229: Nobels for science, biotech dealmaking, & a friendly FTC

    Vom: 6.10.2022